Zou Quan

Monoclonal antibody GK1.5 recognizes a previously undescribed murine T cell surface molecule, designated L3T4, which migrates on SDS-PAGE under reducing conditions as a single band with an apparent m.w. of 52,000. L3T4 is expressed by approximately 80% of thymocytes and by approximately 20% of spleen cells. There appears to be poor correlation between expression of L3T4 by functional T cell clones and expression of Lyt-2, expression of the cytolytic phenotype, and class I MHC antigen reactivity. On the other hand, both a class II MHC antigen-reactive HTL clone and an Lyt-1- Mls-reactive HTL clone express L3T4. Analysis of the effect of mAb GK1.5 on PFC responses in adoptive transfer suggests that L3T4 is expressed by the helper/inducer subset of murine T cells. Expression of L3T4 by murine T cells, however, may correlate primarily with class II MHC antigen reactivity rather than with functional phenotype; mAb GK1.5 profoundly blocks antigen-specific cytolysis by the cloned class II MHC antigen-reactive CTL line A15-1.17. Antigen-specific cytolysis by A15-1.17 is blocked by mAb GK1.5 at a step before the lethal hit. Collectively, the flow cytometric, functional, and biochemical data indicate that L3T4 is similar to the human Leu-3/T4 molecule.

Helicobacter pylori (Hp) infection is the main cause of digestive tract diseases,such as chronic gastritis,gastroduodenal ulcer,gastrointestinal cancer and so on.Nowaday,vaccine has become an effective method to control Hp infection.However,it needs an ideal drug delivery system to achieve an optimal prophylactic effect.In recent years,the research on vaccine delivery system has become a quite active field.This review introduces the research progress in Hp vaccine delivery system,mainly focusing on micro-particle,liposome,freeze-dried powder,multi-emulsion,gel and nanovaccine.

Objective To obtain the recombinant human Helicobacter pylori (Hp) heat shock protein A(HspA) and apply it to clinical diagnosis. Methods The HspA DNA was amplified with PCR from the chromosomal DNA of clinically isolated H. pylori and then inserted into plasmid PinPoint TM Xa 3. The vector pPin HspA was transfected to E.coli JM109 for recombinant protein which were later analyzed with SDS PAGE, Western blot. The purified protein was used with ELISA to test HspA antibody in patients with Hp infection before and after eradication treatment. Results The cloned DNA consisted of 354 base pairs, and encoded 118 amino acid residues with a molecular weight of 14×10 3. Recombinant HspA was confirmed by the sera of Hp infected patients and rabbits with Western blot. The levels of serum anti recombinant HspA antibodies were declined significantly after eradication treatment, but changes of Hp antibodies were not apparent until almost 6 monthes later. Conclusion The identified recombinant HspA protein estabtishes a basis for experimental study on diagnosis, prevention and treatment of Hp infection.

Our results show that the need for third-line is low (5%), but that patients' who switch to third-line ART have good early treatment outcomes and are able to suppress their viral load. Adherence counselling and resistance testing should be prioritized for patients that are at risk of failure, in particular those who never suppress on second-line and those who have been on PI-based regimen for extended periods.